Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NateraMEX:NTRA 60 Market Cap is MXN666,602 Mil as of Jul. 22, 2026. GuruFocus rates MEX:NTRA with a GF Score™ of 60/100 and a GF Value™ of MXN2,983.49 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Natera ranks better than 97.24% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Natera's share price for the quarter that ended in Mar. 2026 was MXN3690. Natera's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 143 Mil. Therefore, Natera's market cap for the quarter that ended in Mar. 2026 was MXN526,688 Mil.
Natera's quarterly market cap
increased
from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN490,581 Mil) and
increased
from Dec. 2025 (MXN490,581 Mil) to Mar. 2026 (MXN526,688 Mil).
Natera's annual market cap
stayed the same
from Dec. 2023 (MXN0 Mil) to Dec. 2024 (MXN0 Mil) but then
increased
from Dec. 2024 (MXN0 Mil) to Dec. 2025 (MXN490,581 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Natera's Enterprise Value for Today is MXN651,832 Mil.
Natera (MEX:NTRA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Natera Market Cap Related Terms
Natera Market Cap Historical Data
* Premium members only.
The historical data trend for Natera's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Natera's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Market Cap distribution charts can be found below:
* The bar in red indicates where Natera's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Natera's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera (MEX:NTRA) has a Market Cap of MXN666,602 Mil as of Jul. 22, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Natera and its competitors. According to the industry distribution chart, Natera ranks #6 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 2.8%.
Is Natera's Market Cap too high?
Natera's current Market Cap is MXN666,602 Mil. Based on the distribution chart, Natera ranks #6 out of 217 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Natera has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's Market Cap compare to WAT and A?
According to the Medical Diagnostics & Research industry distribution chart, Natera ranks #6 out of 217 companies for Market Cap. This places Natera in the top 3% of its industry — outperforming the majority of peers. The industry median Market Cap is 57.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 57.40, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Natera and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 57.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natera's current Market Cap is MXN666,602 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (MEX:NTRA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,983.49, compared to a current price of MXN3,905.00 — trading 30.9% above its estimated fair value. The current Market Cap is MXN666,602 Mil. Natera's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Natera (MEX:NTRA), the current Market Cap is MXN666,602 Mil as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natera (MEX:NTRA) Overvalued in 2026?
Based on GuruFocus' analysis, Natera stock appears to be overvalued.
The current stock price of MXN3,905.00 is trading 30.9% above its estimated GF Value™ of MXN2,983.49.
GuruFocus considers Natera to be Significantly Overvalued.
Key valuation signals for MEX:NTRA:
Market Cap: MXN666,602 Mil
GF Value™: MXN2,983.49 vs. price of MXN3,905.00 (30.9% above fair value)
No single metric tells the full story. See the MEX:NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
60GF Score
Get the complete analysis for MEX:NTRA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NTRA has been successfully added to your 
